Therapeutic Strategy for Diabrtes mellitus by Hepatic Stem cell

有效免疫抑制剂的发展极大地提高了器官移植中的移植物和患者存活率，并在过去几年中促进了医学移植的进步。诱导供体特异性耐受（DST）被广泛认为是解决这些问题最有效的方法。嵌合被认为是诱导DST的一种有吸引力的方法，并且已经发表了许多关于这种现象的研究。将组织不相容的供体小鼠的骨髓（BM）与与受体小鼠组织相容的骨髓一起移植到致死辐照的受体小鼠中，可以形成混合嵌合体，这样受体造血细胞就可以部分被供体相容的细胞取代。与异体嵌合体相比，混合嵌合体更稳定，更不易发生与骨髓移植排斥相关的致死性骨髓发育不全。鉴于其在临床实践中的可用性，我们已将重点放在使用脾细胞作为建立耐受性的细胞来源。脾细胞是一种有吸引力的嵌合细胞来源，因为它们是淋巴细胞的丰富来源。在本研究中，我们验证了含有丰富免疫细胞的脾细胞对维持小鼠嵌合和提高移植物长期存活有效的假设。

The development of effective immunosuppressants has dramatically improved both graft and patient survival rates in organ transplantation, and has contributed to advances in medical transplantation during the past few years. Inducing donor-specific tolerance (DST) is widely believed to be the most effective solution to these problems. Chimerism is viewed as an attractive approach to inducing DST, and many studies of this phenomenon have been published. A mixed chimera can be created by transplanting bone marrow (BM) from histoincompatible donor mice to lethally-irradiated recipient mice, together with BM that is histocompatible with the recipient mice, so that the recipient haematopoietic cells can be partially replaced by donor-compatible cells. Compared to an allochimera, a mixed chimera is more stable and less susceptible to the lethal BM aplasia associated with BM graft rejection. We have focused on using splenocytes as a source of cells for establishing tolerance, in view of their availability for use in clinical practice. Splenocytes are an attractive source of cells with which to develop chimerism because they are a rich source of lymphocytes. In the current study, we verified the hypothesis that splenocytes containing abundant immunocytes are effective for maintaining chimerism and improving long-term graft survival in mice.